Get Four
Free Issues

Subscribe to BW
Customer Service


Full Table of Contents
Cover Story
Up Front
Editor's Memo
Readers Report
Corrections & Clarifications
Technology & You
Media Centric
The Barker Portfolio
Business Outlook
The Business Week



News: Analysis & Commentary
Washington Outlook
The Corporation
People
Science & Technology
Information Technology
Marketing
Finance
Entrepreneurs
Entertainment
Management
Social Issues
Personal Business
Plus
Inside Wall Street
Figures of the Week
Ideas -- Books
Ideas -- The Welch Way
Editorials




JANUARY 30, 2006
INSIDE WALL STREET

Elizabeth Arden's Allure

Elizabeth Arden (RDEN ) is a storied name in fragrance and beauty products, but its stock isn't smelling too sweet these days. It's down from 25 in July to 20 on Jan. 18, mainly because of an October cut in its expected 2006 earnings.


Not So Sweet Just NowPredictably, some analysts have downgraded Arden. But Gary Giblen of Brean Murray, Carret sniffs an opportunity. He has upped the stock from "accumulate" to "strong buy," with a 12-month target of 26. He argues that weak December sales in Europe, which led to Arden's lowered forecast, will be offset by the success there of Prevage, its new anti-aging cream licensed from Allergan (AGN ), the maker of Botox. Arden's new Britney Spears Fantasy perfume is also a hit in Europe, says Giblen. And, he adds, Arden may be a target of perfumer Coty, which recently acquired Unilever's fragrances. Coty says it wants to be No. 1 in all the segments of the global fragrance market -- which means acquisitions. Based on the deal, Arden is worth 38 a share, Giblen figures. The likelihood of a buyout is stronger now, he says. Coty wants to expand in the U.S., and Arden fits the bill, he notes, because Arden is hot in department stores and among high-spending shoppers at discounters such as Target (TGT ), J.C. Penney (JCP ), and Wal-Mart (WMT ). He expects Arden will earn $1.24 a share (above Arden's low-end guidance of $1.20) in the year ending June 30, 2006, on sales of $988 million, and $1.43 in 2007 on $1.1 billion. Goldman Sachs (GS ), with a 5.7% stake, and Morgan Stanley (MWD ), with 4.1%, are among Arden's big investors.

Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.



By Gene G. Marcial
 BW MALL   SPONSORED LINKS
Buy a link now!

Get BusinessWeek directly on your desktop with our RSS feeds.XML

Add BusinessWeek news to your Web site with our headline feed.

Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video.

To subscribe online to BusinessWeek magazine, please click here.

Learn more, go to the BusinessWeekOnline home page

Back to Top



TODAY'S MOST POPULAR STORIES

  1. These Men Could Kill SarbOx
  2. America's Best Place to Raise Your Kids
  3. This Year's Holiday Hit Toy: Zhu Zhu Pets
  4. Wall Street Plays Hardball
  5. Abercrombie & Fitch Bargains for a Rebound

Get Free RSS Feed >>
  MARKET INFO
DJIA 10318.16 -14.28
S&P 500 1091.38 -3.52
Nasdaq 2146.04 -10.78

Portfolio Service Update

Stock Lookup

Enter name or ticker



Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.